Identification of factors associated with aggressive end-of-life antitumour treatment: retrospective study of 1282 patients with cancer.
Philippe DebourdeauMohamed BelkacémiGuillaume Pierre Serge EconomosEric AssénatWerner HilgersJulie CoussirouSfaya Kouidri UzanLéa VasquezAntoine DebourdeauJean Pierre DauresSebastien SalasPublished in: BMJ supportive & palliative care (2020)
Most recent ATT and access to a PCT follow-up are the two most important potentially modifiable factors associated with aggressive EOL in patients with cancer. Early integrated palliative oncology care could help to decrease futile ATT at EOL.